ERBB2 and breast carcinoma: One such study investigated a short exposure to presurgical erlotinib in newly diagnosed breast cancers and showed that in ER+ breast cancers and not HER2+ or triple negative disease, there was a reduction in the phosphorylation of both ER at the S118 site and of MAPK as well as a Ki67 response that was not dependent on EGFR positivity.